Why EPAM Systems Stock Rocketed Higher This Week
Citigroup reduced its price target on EPAM Systems stock. EPAM Systems announced a new partnership with OpenAI.
Market narrative
Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.
Citigroup reduced its price target on EPAM Systems stock. EPAM Systems announced a new partnership with OpenAI.
Stocks
New York, New York--(Newsfile Corp. - August 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GRAIL, Inc. (NASDAQ: GRAL) between May 13, 2025 and February 19, 2026, inclusive (the "Class Period"), of the important August 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased GRAIL common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, Aug. 01, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) between December 27, 2024 and July 8, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 28, 2026.
Fagron NV (ARSUF) Q2 2026 Earnings Call Transcript
New York, New York--(Newsfile Corp. - August 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers or sellers of securities of Genius Group Limited (NYSE American: GNS) between April 12, 2022 and May 30, 2025, inclusive (the "Class Period"), of the important August 28, 2026 lead plaintiff deadline. SO WHAT: If you purchased or sold Genius securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE: KD). On February 9, 2026, the Company disclosed that it would be unable to timely file its Form 10-Q Report for the quarter ended December 31, 2025 and that “the Company anticipates reporting material weaknesses i.
Knorr-Bremse AG (KNRRY) Q2 2026 Earnings Call Transcript
ZOO Digital Group plc (ZDGGF) Q4 2026 Earnings Call Transcript
Snam S.p.A. (SNMRY) Q2 2026 Earnings Call Transcript
Vinci SA (VCISY) Q2 2026 Earnings Call Transcript
Erste Bank Polska S.A. (BKZHF) Q2 2026 Earnings Call Transcript
POSCO Holdings Inc. (PKX) Q2 2026 Earnings Call Transcript
Ilika plc (ILIKF) Q4 2026 Earnings Call Transcript
New York, New York--(Newsfile Corp. - August 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Cogent Communications Holdings, Inc. ("Cogent" or the "Company") (NASDAQ: CCOI) on behalf of investors that purchased or otherwise acquired Cogent securities between February 29, 2024 and May 1, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Cogent and have suffered losses, you may CLICK HERE to contact us.
Applied Materials (AMAT) delivered record Q2 FY2026 revenue of $7.91B (+11% Y/Y) and non-GAAP EPS of $2.86 (+20% Y/Y). Management raised CY2026 equipment growth guidance to 30%+, with improved order visibility and strong DRAM and AGS segment performance. Despite a ~40% drawdown from highs, fundamentals remain robust, and the recent correction is attributed to sector positioning rather than company weakness.
Medicus Pharma (NASDAQ:MDCX) earlier this week announced that the US Food and Drug Administration (FDA) has cleared the company's Phase 2b registration-enabling clinical trial for SkinJect in patients with Gorlin syndrome, representing an important regulatory milestone for its lead investigational asset. Speaking with Proactive, CEO Raza Bokhari said the FDA had approved the company's proposed study following discussions and feedback, allowing Medicus Pharma (NASDAQ:MDCX) to move ahead with a crossover registration study involving up to 50 patients.
New York, New York--(Newsfile Corp. - August 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Futu Holdings Limited (NASDAQ: FUTU) between May 24, 2023 and May 27, 2026, inclusive (the "Class Period"), of the important August 25, 2026 lead plaintiff deadline. SO WHAT: If you purchased Futu securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Skyworks Solutions, Inc. (NasdaqGS: SKW) (“Skyworks” or the “Company”). On February 5, 2025, the Company announced its financial results for the first quarter of fiscal year 2025, disclosing lower-than anticipated revenue guidance for the second quarter of fiscal year 202.
Collegium Pharmaceutical (COLL) is transitioning from a pain-management roll-up to a CNS platform, leveraging stable pain cash flows to fuel ADHD franchise growth. The AZSTARYS acquisition, funded with $350M cash and $300M debt, is expected to deliver $60–70M revenue in 2026 and $50M+ annual synergies within 12 months. COLL's 2026 guidance is $865–895M in revenue and $475–500M adjusted EBITDA, with a 55% margin, reflecting only partial-year AZSTARYS contribution and early synergies.
Bloom Energy reported stellar results for the second quarter of 2026, surpassing $1 billion in quarterly revenue for the first time. The energy technology company also reported a profit of $196.2 million.